Profil bibliographique

Iqtedar A Muazzam

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

28Publications signalées

2352Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Renal cell carcinoma treatmentCOVID-19 Clinical Research StudiesVenous Thromboembolism Diagnosis and ManagementEconomic and Financial Impacts of CancerHepatocellular Carcinoma Treatment and Prognosis

Publications récentes

Accès ouvert 2025 articleOpenAlex

Real-world effectiveness and safety of avelumab + axitinib combination in first-line treatment of UK patients with advanced renal cell carcinoma

Paul Nathan, Natalie Charnley, Ricky Frazer, John McGrane et autres

0 citationsESMO Real World Data and Digital Oncology

Accès ouvert 2025 articleOpenAlex

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

Gianmarco Leone, Francesco Orlando, Peter Dutey‐Magni, Osvaldas Vainauskas et autres

5 citationsJAMA Oncology

Accès ouvert 2024 conference-paperOpenAlex

Influence of immunotherapy combinations on outcomes in sarcomatoid metastatic renal cell carcinoma: results from the UK Renal Oncology Collaborative

Pritha Roy, Isobel Irwin, Ricky Frazer, John McGrane et autres

0 citations

Accès ouvert 2024 articleOpenAlex

Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the UK Renal Oncology Collaborative ( UK ROC ): Is it time to look favourably on first‐line immunotherapy containing combinations in all IMDC groups?

John McGrane, Ricky Frazer, Amarnath Challapalli, Gihan Ratnayake et autres

4 citationsCancer Medicine

2024 conference-abstractOpenAlex

Real world outcomes for maintenance avelumab treatment in locally advanced/metastatic urothelial cancer after platinum-based chemotherapy.

Ahmed Rehan, Muneeb Qureshi, Sabin Göktaş Aydın, Kate O’Connor et autres

1 citationJournal of Clinical Oncology

2024 conference-abstractOpenAlex

A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.

Paul Nathan, Natalie Charnley, Ricky Frazer, John McGrane et autres

4 citationsJournal of Clinical Oncology

Accès ouvert 2024 articleOpenAlex

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

Saul N. Faust, Richard Haynes, Christine E. Jones, Natalie Staplin et autres

40 citationsThe Lancet Child & Adolescent Health

Accès ouvert 2023 conference-abstractOpenAlex

The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre.

Justin KH Liu, Andrew F. Irvine, Mustafa Altarqane, Mariyam Arif et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2023 conference-abstractOpenAlex

A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results.

Paul Nathan, Natalie Charnley, Ricky Frazer, John McGrane et autres

2 citationsJournal of Clinical Oncology

Accès ouvert 2022 articleOpenAlex

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

Obbina Abani, Ali Abbas, Fatima Abbas, Joshua Abbas et autres

334 citationsThe Lancet

2022 conference-abstractOpenAlex

Avelumab plus axitinib in advanced renal cell carcinoma (aRCC): 12-month interim results from a real-world observational study in the United Kingdom.

Paul Nathan, Iqtedar A Muazzam, Ricky Frazer, Anand Sharma et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2022 articleOpenAlex

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas, Mustafa Abbas et autres

384 citationsThe Lancet

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.